BERN, Switzerland: Protocol AI accelerates clinical trial development and patient access to medical devices BERN, Switzerland , Jan. 22, 2025 /PRNewswire/ — Risklick, a spin-off from the University of Bern, has launched its latest product, Protocol AI, for medical devices. Protocol AI is the first software of its kind and marks a turning point in the medical device industry. It uses artificial intelligence to accelerate the development of clinical trials while drastically reducing associated costs and risks. This accelerated timeline benefits patients, granting them quicker access to new treatments—potentially at a lower cost. This innovative technology has demonstrated its potential to revolutionize clinical trials for medical products and is now ready to provide millions of patients with faster access to life-saving medical devices worldwide.